新冠疫苗接种对每月偏头痛天数的影响：一项纵向队列研究。

Effect of COVID vaccination on monthly migraine days: a longitudinal cohort study.

机构信息

Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.

Department of Internal Medicine, Erasmus University, Rotterdam, The Netherlands.

出版信息

Cephalalgia. 2023 Sep;43(9):3331024231198792. doi: 10.1177/03331024231198792.

DOI:10.1177/03331024231198792

PMID:37684012

Abstract

BACKGROUND

This longitudinal cohort study aimed to investigate changes in migraine-related outcomes following COVID-19 infection and vaccination.

METHODS

We identified 547 clinically diagnosed migraine patients from the Leiden Headache Center who kept a headache E-diary during the COVID-19 pandemic (February 2020 to August 2022). We sent a questionnaire to register their COVID-19 infection and/or vaccination dates. After applying inclusion criteria, n = 59 participants could be included in the infection analysis and n = 147 could be included in the vaccination analysis. Primary outcome was the change in monthly migraine days (MMD) between 1 month prior and 1 month post COVID-19 infection or vaccination. Secondary outcome variables were change in monthly headache days (MHD) and monthly acute medication days (MAMD).

RESULTS

Vaccination against COVID-19 was associated with an increase in MMD (1.06; 95% confidence interval [CI] = 0.57-1.55; < 0.001), MHD (1.52; 95% CI = 0.91-2.14; < 0.001) and MAMD (0.72; 95% CI = 0.33-1.12; < 0.001) in the first month post-vaccination. COVID-19 infection solely increased the number of MAMD (1.11; 95% CI = 0.10-1.62; < 0.027), but no statistically significant differences in MMD or MHD were observed.

CONCLUSIONS

Our findings imply that vaccination against COVID-19 is associated with an increase in migraine, indicating a possible role of inflammatory mediators in migraine pathophysiology.

摘要

背景

本纵向队列研究旨在探讨 COVID-19 感染和接种疫苗后偏头痛相关结局的变化。

方法

我们从莱顿头痛中心确定了 547 名经临床诊断的偏头痛患者，他们在 COVID-19 大流行期间（2020 年 2 月至 2022 年 8 月）保持头痛电子日记。我们发送了一份问卷，以登记他们的 COVID-19 感染和/或疫苗接种日期。应用纳入标准后，n=59 名参与者可纳入感染分析，n=147 名参与者可纳入疫苗接种分析。主要结局是 COVID-19 感染或疫苗接种前后 1 个月内每月偏头痛天数（MMD）的变化。次要结局变量是每月头痛天数（MHD）和每月急性药物天数（MAMD）的变化。

结果

COVID-19 疫苗接种与 MMD（1.06；95%置信区间 [CI] = 0.57-1.55； < 0.001）、MHD（1.52；95% CI = 0.91-2.14； < 0.001）和 MAMD（0.72；95% CI = 0.33-1.12； < 0.001）在接种疫苗后第一个月增加有关。COVID-19 感染仅增加了 MAMD（1.11；95% CI = 0.10-1.62； < 0.027）的数量，但 MMD 或 MHD 没有观察到统计学上的显著差异。